BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oral vernakalant: Development resumed

Cardiome said partner Merck has completed its review of oral vernakalant and plans to begin the next steps of clinical development for the mixed ion channel antagonist in 2011. Merck said the next steps would begin with Phase I and Phase II studies of the AF candidate. In August, Cardiome said...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >